Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer

Alberto Riccardi, Silvia Brugnatelli, Monica Giordano, Marco Danova, Palma Pugliese, Carmine Tinelli, Catherine Klersy, Antonella Richetti, Sergio Fava, Giuseppe Nastasi, Elena Rinaldi, Vittorio Fregoni, Andrea De Monte, Giovanni Trotti, Antonella Bovio, Edoardo Ascari

Research output: Contribution to journalArticle

Abstract

Aims and background: The neutropenia induced by six courses of an intensified FEC regimen is expected to be checked by early primary administration of G-CSF which is stopped eight days before the next chemotherapy course. Less information is available about megakaryocytic and erythroid toxicity over six courses. Methods and study design: Sixty-six consecutive patients with metastatic breast cancer completed six courses of a randomized treatment with two FEC regimens administered every 21 days, in which 600 mg/m2 of cyclophosphamide and 5-FU was associated with 60 or 120 mg/m2 of epirubicin (60FEC, 35 patients, vs 120FEC, 31 patients). 120FEC was supported by early primary G-CSF (days 4 to 13). Blood counts were obtained seven times during each course. Results: The non-hematologic toxicity over 364 courses was similar in 60FEC and 120FEC. No cumulative hematologic toxicity was observed for white blood cells (WBC) and platelets (PLT), while for hemoglobin (Hb) a somewhat higher cumulative toxicity was observed with 120FEC than with 60FEC. WBC, PLT and Hb grade III-IV toxicity occurred in 40.1% and 45.6% (P=ns), in 23.1% and 0.8% (P

Original languageEnglish
Pages (from-to)540-546
Number of pages7
JournalTumori
Volume84
Issue number5
Publication statusPublished - 1998

Keywords

  • Advanced breast cancer
  • Dose intensity
  • Epirubicin
  • G-CSF
  • Myeloprotection

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Riccardi, A., Brugnatelli, S., Giordano, M., Danova, M., Pugliese, P., Tinelli, C., Klersy, C., Richetti, A., Fava, S., Nastasi, G., Rinaldi, E., Fregoni, V., De Monte, A., Trotti, G., Bovio, A., & Ascari, E. (1998). Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Tumori, 84(5), 540-546.